Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families

Deborah Ford, Douglas F. Easton, Michael R. Stratton, +35

The American Journal of Human Genetics

Risks of Breast, Ovarian, and Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers

Karoline Kuchenbaecker, John L. Hopper, Daniel R. Barnes, +56

JAMA

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

Jack Cuzick, Ivana Šestak, Michael Baum, +4

The Lancet Oncology

Breast OncologyOncologyAtac TrialPharmacologyAdjuvant Treatment +6

Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: The PROSE Study Group

Timothy R. Rebbeck, Tara M. Friebel, Henry T. Lynch, +10

Journal of Clinical Oncology

Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update

Harold J. Burstein, Sarah Temin, Holly Anderson, +10

Journal of Clinical Oncology

Breast Cancer Risk After Bilateral Prophylactic Oophorectomy in BRCA1 Mutation Carriers

Timothy R. Rebbeck, Albert M. Levin, Andrea Eisen, +12

JNCI Journal of the National Cancer Institute

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

Paul E. Goss, James N. Ingle, Kathleen I. Pritchard, +17

New England Journal of Medicine

Contralateral Breast Cancer in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers

Kelly Metcalfe, Henry T. Lynch, Parviz Ghadirian, +10

Journal of Clinical Oncology

Adjuvant Tamoxifen Therapy for Early Stage Breast Cancer and Second Primary Malignancies

Lars Erik Rutqvist, Hemming Johansson, T. Signomklao, +3

JNCI Journal of the National Cancer Institute

Ten-Year Multi-Institutional Results of Breast-Conserving Surgery and Radiotherapy in <i>BRCA1/2</i>-Associated Stage I/II Breast Cancer

Lori J. Pierce, Albert M. Levin, Timothy R. Rebbeck, +17

Journal of Clinical Oncology